Raphael Pharmaceutical Inc
easy-energy.bizWhat Do They Do?
Develops cannabinoid-based drug therapies for patients with rheumatoid arthritis and asthma, alongside a dietary supplement for rheumatoid arthritis support.
10-K for FY2025, filed Mar 31, 2026We are a pharmaceutical drug research and development company focused on the discovery and clinical development of life-improving drug…View ↗
In August 2025, we announced the completion of product development and the launch of our proprietary natural formula under the “RaphaWell”…View ↗
In December 2024, we completed the Study for our lead product candidate for the treatment of RA, and are currently developing novel asthma…View ↗
Who Are Their Customers?
RaphaWell is intended as a standalone supplement for the wellness market; approved drug products would be made and distributed through third-party medical manufacturers and distributors.
10-K for FY2025, filed Mar 31, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$223KView ↗
- ▼ −31% (Loss)
- vs −$322K in Q2 FY2025
-
Sep 1, 2026
Signs AI services agreement that contemplates a branded token platform
AIcreatesAI will provide managed services; the agreement also contemplates a branded token platform, subject to board approval.
Sources
8-K, filed Sep 1, 2026
On July 30, 2026, Raphael Pharmaceutical Inc. (the “Company”) entered into an Enterprise AI Transformation and Growth Partnership with…View ↗
-
Jul 17, 2026
Chairman and CFO resign; company appoints a new CFO
The chairman and director resigned effective June 30; the CFO and director resigned July 16, and Uri Tadelis was appointed CFO.
Sources
8-K, filed Jul 17, 2026
Mr. Ajay Kumar Dhadha voluntarily resigned from his positions as Chairman of the Board of Directors and Director of the Company, effective…View ↗
Loading...
